A Multicenter, Double-blind, Parallel Phase III Study
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: GC Flu(Trivalent)Biological: GC3110A(Quadrivalent)Biological: GC3110A(Trivalent)
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 1299
- Registration Number
- NCT02352584
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
Phase 1
- Conditions
- Colorectal CancerGastric CancerNeoplasm Metastasis
- Interventions
- Biological: GC1118
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT02352571
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
Phase 2
- Conditions
- Gastritis
- Interventions
- Drug: PlaceboDrug: GC6101A 150mgDrug: GC6101A 75mgDrug: GC6101A 37.5mg
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT02353039
- Locations
- 🇰🇷
Inje University, Busan Paik Hospital of Korea, Busan, Korea, Republic of
🇰🇷Keimyung University, Dongsan Medical Center of Korea, Daegu, Korea, Republic of
🇰🇷Wonkwang University, Hospital of Korea, Iksan-si, Korea, Republic of
A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
Phase 2
Completed
- Conditions
- Hepatitis B Infection
- Interventions
- Biological: GC1102 50,000 IUBiological: GC1102 80,000 IU
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT02304315
- Locations
- 🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of
Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Trivalent influenza vaccineBiological: Quadrivalent cell-culture based influenza vaccin
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT02249221
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Quadrivalent influenza vaccineBiological: Trivalent influenza vaccine
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT02121782
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.
Phase 4
Completed
- Conditions
- Prevention of Influenza
- Interventions
- Drug: GC FLU® Injection, GC FLU® Pre-filled Syringe Injection
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 1139
- Registration Number
- NCT02067117
A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule
- Conditions
- Osteoarthritis
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 6700
- Registration Number
- NCT02064634
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Sonpa-gu, Korea, Republic of
An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
Phase 3
Completed
- Conditions
- Immune Thrombocytopenia
- Interventions
- Drug: Human immunoglobulin intravenous
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT02063789
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Deagu, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of
The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
- Conditions
- Hunter Syndrome
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT02044692
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of